Journal Article

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Reck, Martin, Rodriguez-Abreu, Delvys, Carbone, David P, van den Heuvel, Michel M, Badin, Firas, Peters, Solange, Villaruz, Liza C, Ready, Neal, Wrangle, John M, Juergens, Rosalyn, Steins, Martin, Hiltermann, T. Jeroen N, Horn, Leora, Nair, Suresh, Krejci, Jana, Chen, Allen C, Paz-Ares, Luis, Chang, Han, Felip, Enriqueta, Borghaei, Hossein, Creelan, Benjamin, Corral Jaime, Jesus, Geese, William J, Havel, Libor, Socinski, Mark A, Minenza, Elisa, Blumenschein, George R, Ciuleanu, Tudor-Eliade, Bhagavatheeswaran, Prabhu

2017

Overview

Although pembrolizumab has appeared to be more effective than chemotherapy in patients with lung cancer whose tumors had at least 50% PD-L1–positive cells, nivolumab was not as effective as chemotherapy in patients with lung cancer whose tumors had PD-L1 expression of at least 5%. For the past two decades, platinum-based combination chemotherapy has been the standard-of-care, first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) without mutations that were sensitive to targeted therapy. 1 , 2 However, chemotherapy has provided only a moderate benefit, with a limited safety profile. In phase 3 clinical trials, the median progression-free survival with platinum-based chemotherapy was 4 to 6 months, and the median overall survival was 10 to 13 months. 3 – 8 In two phase 3 trials, nivolumab, a programmed death 1 (PD-1) immune-checkpoint–inhibitor antibody, resulted in significantly longer overall survival than docetaxel among patients with metastatic NSCLC who had . . .

• Publisher: Massachusetts Medical Society
• Subject: Antineoplastic Agents / Apoptosis / B7-H1 Antigen - metabolism / Body weight / Cancer therapies / Carcinoma, Non-Small-Cell Lung - chemically induced / Chemotherapy / Clinical trials / Death / Disease-Free Survival / Humans / Immunotherapy / Ligands / Lung cancer / Lung Neoplasms - chemically induced / Lungs / Metastasis / Monoclonal antibodies / Mutation / Non-small cell lung carcinoma / Oncology / Onkologi / PD-L1 protein / Platinum / Survival / Targeted cancer therapy